Antiphospholipid syndrome

被引：0

作者：

Cervera, Ricard ^{[1
]}

机构：

[1] Hosp Clin Barcelona, Dept Autoimmune Dis, Barcelona, Catalonia, Spain

来源：

THROMBOSIS RESEARCH | 2017年 / 151卷

关键词：

Antiphospholipid syndrome; Anticardiolipin antibodies; Lupus anticoagulant; Catastrophic antiphospholipid syndrome; INTERNATIONAL CONSENSUS STATEMENT; CLASSIFICATION CRITERIA; CAPS REGISTRY; DESCRIPTIVE ANALYSIS; MORTALITY; MORBIDITY; MANIFESTATIONS; PREVENTION; ANTIBODIES; THROMBOSIS;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The antiphospholipid syndrome (APS) is defined by the development of venous and/or arterial thromboses, often multiple, and pregnancy morbidity (mainly, recurrent fetal losses), in the presence of antiphospholipid antibodies (aPL). Some estimates indicate that the incidence of the APS is around 5 new cases per 100,000 persons per year and the prevalence around 40-50 cases per 100,000 persons. The aPL are positive in approximately 13% of patients with stroke, 11% with myocardial infarction, 9.5% of patients with deep vein thrombosis and 6% of patients with pregnancy morbidity. Currently, there is consensus in treating APS patients with thrombosis with long-term oral anticoagulation and to prevent obstetric manifestations with the use of aspirin and heparin. This review summarizes the main knowledge on the clinical and therapeutic aspects of this syndrome. (C) 2017 Elsevier Ltd. All rights reserved.

引用

页码：S43 / S47

页数：5

共 31 条

[1]

Andrade D, 2017, APS CURRENT RES HIGH

[2] Estimated Frequency of Antiphospholipid Antibodies in Patients With Pregnancy Morbidity, Stroke, Myocardial Infarction, and Deep Vein Thrombosis: A Critical Review of the Literature [J].

Andreoli, Laura ;

Chighizola, Cecilia B. ;

Banzato, Alessandra ;

Pons-Estel, Guillermo J. ;

de Jesus, Guilherme Ramire ;

Erkan, Doruk .

ARTHRITIS CARE & RESEARCH, 2013, 65 (11) :1869-1873

[3]

[Anonymous], 2016, ANTIPHOSPHOLIPID SYN

[4] Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines [J].

Asherson, RA ;

Cervera, R ;

de Groot, PG ;

Erkan, D ;

Boffa, MC ;

Piette, JC ;

Khamashta, MA ;

Shoenfeld, Y .

LUPUS, 2003, 12 (07) :530-534

[5] Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab [J].

Berman, Horacio ;

Rodriguez-Pinto, Ignasi ;

Cervera, Ricard ;

Morel, Nathalie ;

Costedoat-Chalumeau, Nathalie ;

Erkan, Doruk ;

Shoenfeld, Yehuda ;

Espinosa, Gerard .

AUTOIMMUNITY REVIEWS, 2013, 12 (11) :1085-1090

[6] Antiphospholipid syndrome -: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients [J].

Cervera, R ;

Piette, JC ;

Font, J ;

Khamashta, MA ;

Cervera, R ;

Piette, JC ;

Font, J ;

Khamashta, MA ;

Shoenfeld, Y ;

Camps, MT ;

Jacobsen, S ;

Lakos, G ;

Tincani, A ;

Kontopoulou-Griva, I ;

Galeazzi, M ;

Meroni, PL ;

Derksen, RHWM ;

de Groot, PG ;

Gromnica-Ihle, E ;

Baleva, M ;

Mosca, M ;

Bombardieri, S ;

Houssiau, F ;

Gris, JC ;

Quéré, I ;

Hachulla, E ;

Vasconcelos, C ;

Roch, B ;

Fernández-Nebro, A ;

Boffa, MC ;

Hughes, GRV ;

Ingelmo, M .

ARTHRITIS AND RHEUMATISM, 2002, 46 (04) :1019-1027

[7] Antiphospholipid syndrome associated with infections:: clinical and microbiological characteristics of 100 patients [J].

Cervera, R ;

Asherson, RA ;

Acevedo, ML ;

Gómez-Puerta, JA ;

Espinosa, G ;

de la Red, G ;

Gil, V ;

Ramos-Casals, M ;

García-Carrasco, M ;

Ingelmo, M ;

Font, J .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (10) :1312-1317

[8] Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome [J].

Cervera, R ;

Font, J ;

Gómez-Puerta, JA ;

Espinosa, G ;

Cucho, M ;

Bucciarelli, S ;

Ramos-Casals, M ;

Ingelmo, M ;

Piette, JC ;

Shoenfeld, Y ;

Asherson, RA .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1205-1209

[9] Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients [J].

Cervera, R. ;

Serrano, R. ;

Pons-Estel, G. J. ;

Ceberio-Hualde, L. ;

Shoenfeld, Y. ;

de Ramon, E. ;

Buonaiuto, V. ;

Jacobsen, S. ;

Zeher, M. M. ;

Tarr, T. ;

Tincani, A. ;

Taglietti, M. ;

Theodossiades, G. ;

Nomikou, E. ;

Galeazzi, M. ;

Bellisai, F. ;

Meroni, P. L. ;

Derksen, R. H. W. M. ;

de Groot, P. G. D. ;

Baleva, M. ;

Mosca, M. ;

Bombardieri, S. ;

Houssiau, F. ;

Gris, J-C ;

Quere, I. ;

Hachulla, E. ;

Vasconcelos, C. ;

Fernandez-Nebro, A. ;

Haro, M. ;

Amoura, Z. ;

Miyara, M. ;

Tektonidou, M. ;

Espinosa, G. ;

Bertolaccini, M. L. ;

Khamashta, M. A. .

ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (06) :1011-1018

[10] Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients [J].

Cervera, R. ;

Khamashta, M. A. ;

Shoenfeld, Y. ;

Camps, M. T. ;

Jacobsen, S. ;

Kiss, E. ;

Zeher, M. M. ;

Tincani, A. ;

Kontopoulou-Griva, I. ;

Galeazzi, M. ;

Bellisai, F. ;

Meroni, P. L. ;

Derksen, R. H. W. M. ;

de Groot, P. G. ;

Gromnica-Ihle, E. ;

Baleva, M. ;

Mosca, M. ;

Bombardieri, S. ;

Houssiau, F. ;

Gris, J-C ;

Quere, I. ;

Hachulla, E. ;

Vasconcelos, C. ;

Roch, B. ;

Fernandez-Nebro, A. ;

Piette, J-C ;

Espinosa, G. ;

Bucciarelli, S. ;

Pisoni, C. N. ;

Bertolaccini, M. L. ;

Boffa, M-C ;

Hughes, G. R. V. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (09) :1428-1432

← 1 2 3 4 →